Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Fresenius Kabi Ltd.

Fresenius Kabi is the leading European provider of clinical nutrition and infusion therapy offering a unique and comprehensive range of products and services for both hospital and home settings. From our expertise in nutrition and infusion therapies, and through dedication to people through innovation we are committed to becoming the preferred partner worldwide for saving, treatment and caring for chronically ill patients.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

No items found

Company Details

Fresenius Kabi Ltd.
Cestrian Court, Eastgate Way, Runcorn, Cheshire, WA7 1NT
+44 (0) 1928-533 533
Contact Fresenius Kabi Ltd.
Website

 Latest Content from PMHub 

Case study: Leveraging Market Research Data to Inform Healthcare Providers and the Community

White Papers and Resources | November 23, 2016 | Inizio

Our client wanted to understand why uptake of HPV vaccination in the Asia-Pacific region was limited.  In order to help increase uptake, they wanted to publish the market research findings...

Towards a culture of evaluation and evidence-based decision making in global health

White Papers and Resources | November 23, 2016 | Inizio

Reflections on THET Conference 2016: Evidence, Effectiveness & Impact

Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016

White Papers and Resources | November 23, 2016 | Inizio

Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe. Living with UC is a quantitative study conducted online amongst 325 patients, including...

The Internet of Things

White Papers and Resources | November 23, 2016 | Inizio

Evolution from man to machine

Therapy Watch expands its oncology portfolio

White Papers and Resources | November 23, 2016 | Inizio

This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). Therapy Watch SCCHN is part of a wider portfolio...

Time for a new language for asthma?

White Papers and Resources | November 23, 2016 | Inizio

Despite the global advances made in the treatment for asthma, many studies have shown that asthma remains uncontrolled for a large proportion of patients, when assessed according to international guidelines....

Evaluating the impact of your medical congress presence…more cost effectively

White Papers and Resources | November 23, 2016 | Inizio

Organising a company’s presence, not just logistically, but in terms of delivering key information, data and messages, is a massive part of some people’s workload at this time of year....

Delivering multi-stakeholder patient journey insights in oncology with creative outputs and data visualisation

White Papers and Resources | November 23, 2016 | Inizio

Two clients were co-developing a product and needed to understand the patient journey in two areas of oncology, in order to identify the leverage points where they could provide an...

Webinar: Understanding Patient Willingness to Pay

White Papers and Resources | November 23, 2016 | Inizio

What steps should pharma and medical device companies take to ensure they get their pricing strategy right in self-pay markets?

Research Partnership welcomes 22 new Graduates

White Papers and Resources | November 23, 2016 | Inizio

As part of our continued growth, we are delighted to announce a new intake of 17 Research Analysts and 5 Fieldwork Project Coordinators into our annual market research graduate programme.http://www.researchpartnership.com/news/2016/09/new-graduates-2016/